Our objective is to examine “coverage, price, and reimbursement” (“CPR”) for multigene tests broadly and for cancer-related indications, specifically, why tests are covered/not covered by payers, how this is changing over time, and how CPR influences testing decisions and practices in clinic settings.
Prime PI is Kathryn A. Phillips, Ph.D., UCSF. Site PI is Su-Ying Liang, Ph.D.
National Institutes of Health - National Cancer Institute
July 01, 2018
June 30, 2021